Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity

Cancer Prevention Research

Volumn 5, Issue 5, 2012, Pages 717-725

  Zhang, Qi ^a,c   Pan, Jing ^a,c   North, Paula E ^b   Yang, Shoua ^b   Lubet, Ronald A ^b   Wang, Yian ^a   You, Ming ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BENZO[A]PYRENE; BROMOPYRUVIC ACID; CASPASE 3; HEXOKINASE; UNCLASSIFIED DRUG; PYRUVIC ACID DERIVATIVE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; ENERGY METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER TOXICITY; LUNG CARCINOGENESIS; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ADENOCARCINOMA; ANIMAL; BIOLOGICAL MODEL; CELL SURVIVAL; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; INHALATIONAL DRUG ADMINISTRATION; LUNG TUMOR; PATHOLOGY; TOXIC HEPATITIS; TUMOR CELL LINE;

ADENOCARCINOMA; ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MODELS, BIOLOGICAL; PYRUVATES;

EID: 84866260153     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0338     Document Type: Article

References (28)

1. Jemal A, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 2000;130(2S Suppl):467S-471S.
3. William WN Jr., et al. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 2009;8:213-25.
4. Wattenberg LW. Chemoprevention of cancer. Cancer Res 1985;45:1-8. (Pubitemid 15196921)
5. Khuri FR, Cohen V. Molecularly targeted approaches to the chemoprevention of lung cancer. Clin Cancer Res 2004;10(12 Pt 2):4249s-4253s. (Pubitemid 38812456)
6. Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 2003;63:3847-54. (Pubitemid 36917892)
7. Pelicano H, et al. Glycolysis inhibition for anticancer treatment. Oncogene 2006;25:4633-46. (Pubitemid 44187614)
8. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006;25:4777-86. (Pubitemid 44187625)
9. Cao X, Bloomston M, Zhang T, Frankel WL, Jia G, Wang B, et al. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res 2008;14:1831-9. (Pubitemid 351469470)
10. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res 2009;29:4909-18.
11. Liu XH, Zheng XF, Wang YL. Inhibitive effect of 3-bromopyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction. Chin Med J (Engl) 2009;122:1681-5.
12. Pereira da Silva AP, El-Bacha T, Kyaw N, dos Santos RS, da-Silva WS, Almeida FC, et al. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J 2009;417:717-26.
13. Yan Y, Lu Y, Wang M, Vikis H, Yao R, Wang Y, et al. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. Mol Cancer Res 2006;4:971-81. (Pubitemid 46121555)
14. Zhang Q, Fu H, Pan J, He J, Ryota S, Hara Y, et al. Effect of dietary Polyphenon E and EGCG on lung tumorigenesis in A/J Mice. Pharm Res 2010;27:1066-71.
15. Wang Y, Wen W, Yi Y, Zhang Z, Lubet RA, You M. Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer. Cancer Prev Res 2009;2:1059-64.
16. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005;65:613-21.
17. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 2011;208:313-26.
18. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003;22:8543-67. (Pubitemid 38028527)
19. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 1997;22:299-306. (Pubitemid 27327087)
20. Ihrlund LS, Hernlund E, Khan O, Shoshan MC. 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol 2008;2:94-101.
21. Thangaraju M, Karunakaran SK, Itagaki S, Gopal E, Elangovan S, Prasad PD, et al. Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. Cancer 2009;115:4655-66.
22. Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 2009;113:2014-21.
23. Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 1997;29:339-43.
24. Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and in flammatory lesions of the lung. Neoplasia 2005;7:369-79. (Pubitemid 40664226)
25. Lu Y, Yao R, Yan Y, Wang Y, Hara Y, Lubet RA, et al. A gene expression signature that can predict green tea exposure and chemopreventive efficacy of lung cancer in mice. Cancer Res 2006;66:1956-63.
26. Johnson TE, Kassie F, O'Sullivan MG, Negia M, Hanson TE, Upadhyaya P, et al. Chemopreventive effect of kava on 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone plus benzo[a]pyrene-induced lung tumorigenesis in A/J mice. Cancer Prev Res 2008;1:430-8.
27. Kim JS, Ahn KJ, Kim JA, Kim HM, Lee JD, Lee JM, et al. Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells: ROS-mediated cell death by 3-BrPA. J Bioenerg Biomembr 2008;40:607-18.
28. Kim W, Yoon JH, Jeong JM, Cheon GJ, Lee TS, Yang JI, et al. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol Cancer Ther 2007;6:2554-62. (Pubitemid 47480421)